Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 2 | 4 | 2 | — | — | 7 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | — | 2 | — | — | 4 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 1 | 1 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 12 | 1 | — | — | — | 12 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 2 | — | — | — | 3 |
Colorectal neoplasms | D015179 | — | — | 1 | 2 | — | — | — | 2 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 2 | — | — | — | 2 |
Malignant mesothelioma | D000086002 | — | — | 1 | 2 | — | — | — | 2 |
Head and neck neoplasms | D006258 | — | — | — | 1 | — | — | — | 1 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | — | 1 | — | — | — | 1 |
Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
Small cell carcinoma | D018288 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | — | — | — | — | 1 |
Drug common name | Tivantinib |
INN | tivantinib |
Description | LSM-1131 is a member of indoles. |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12 |
PDB | — |
CAS-ID | 905854-02-6 |
RxCUI | — |
ChEMBL ID | CHEMBL2103882 |
ChEBI ID | — |
PubChem CID | 11494412 |
DrugBank | — |
UNII ID | PJ4H73IL17 (ChemIDplus, GSRS) |